Optimal management of chronic heart failure in patients with chronic kidney disease.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of renal care

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1755-6686.2009.00069.xPMID 19200271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atherosclerotic renovascular disease

  2010cited by this paper
• Ultrafiltration in the management of heart failure

  2008cited by this paper
• Systolic dysfunction portends increased mortality among those waiting for renal transplant.

  2008cited by this paper
• Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.

  2007cited by this paper
• Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

  2007cited by this paper
• Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.

  2007cited by this paper
• Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction

  2007cited by this paper
• [Candesartan in heart failure: assessment of reduction in mortality and morbidity].

  2007influential reference
• Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

  2007cited by this paper
• Vasopressin receptor antagonists in heart failure.

  2006cited by this paper
• Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure

  2006cited by this paper
• Efficacy and safety of benazepril for advanced chronic renal insufficiency.

  2006influential reference
• Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study

  2006cited by this paper
• Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH).

  2006influential reference
• Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.

  2006cited by this paper
• Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

  2005influential reference
• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

  2005influential reference
• Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.

  2005influential reference
• The effect of cardiac resynchronization on morbidity and mortality in heart failure.

  2005cited by this paper
• Left ventricular morphology and function in patients with atherosclerotic renovascular disease.

  2005cited by this paper
• Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis.

  2005cited by this paper
• Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

  2005cited by this paper
• Cardiology and nephrology: time for a more integrated approach to patient care?

  2005influential reference
• Cardiac resynchronisation therapy: an option for inotrope‐supported patients with end‐stage heart failure?

  2005cited by this paper
• Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure?

  2005cited by this paper
• Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study

  2004cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Haemoglobin concentration and prognosis in new cases of heart failure.

  2003cited by this paper
• Effect of anemia on exercise tolerance in chronic heart failure in men.

  2003cited by this paper
• Vasopressin receptor antagonists in heart failure.

  2003cited by this paper
• Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration.

  2002cited by this paper
• Coronary artery disease as the cause of incident heart failure in the population.

  2001cited by this paper
• Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

  2001cited by this paper
• Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

  2000cited by this paper
• THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• The clinical epidemiology of cardiac disease in chronic renal failure.

  1999cited by this paper
• Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

  1999influential reference
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Hormones and hemodynamics in heart failure.

  1999cited by this paper
• Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

  1998cited by this paper
• The effect of digoxin on mortality and morbidity in patients with heart failure.

  1997cited by this paper
• The origin of symptoms in chronic heart failure

  1997cited by this paper
• Origin of symptoms in chronic heart failure

  1997cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

  1995influential reference
• Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial).

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease and cardiac failure. Semin Dial 2003

  year unknowncited by this paper

• Cardiorenal syndrome: epidemiology, pathogenesis, and outcomes

  2011cites this paper
• Four extremity fractures in a patient with renal osteodystrophy.

  2010cites this paper
• Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure.

  2010cites this paper